A 32-year-old man from rural Odisha presents to the emergency department with a 5-day history of fever, chills, and headache. On examination, he is febrile (39.5°C), with mild jaundice and hepatosplenomegaly. Laboratory investigations reveal: Hb 9.2 g/dL, platelets 65,000/μL, creatinine 2.1 mg/dL, and bilirubin 3.8 mg/dL (predominantly indirect). Thick and thin blood smears show ring forms and Maurer's clefts. What is the most appropriate immediate management?

Explanation

## Clinical Recognition **Key Point:** The blood smear findings (ring forms and Maurer's clefts) confirm *Plasmodium falciparum* malaria. The presence of severe features—acute kidney injury (creatinine 2.1), thrombocytopenia (65,000), jaundice with hyperbilirubinemia, and anemia—indicates **severe malaria** requiring parenteral artesunate or artemether. ## Severe Malaria Criteria This patient meets WHO criteria for severe malaria: - Acute kidney injury (Cr >3 mg/dL or Cr >2× baseline) - Severe thrombocytopenia (<50,000/μL) - Jaundice with elevated bilirubin - Parasitemia likely high (given clinical severity) ## Treatment Algorithm ```mermaid flowchart TD A[P. falciparum malaria]:::outcome --> B{Severe features?}:::decision B -->|Yes| C[Parenteral artesunate or artemether]:::action B -->|No| D[Oral ACT artemisinin-based combination]:::action C --> E[Artesunate 2.4 mg/kg IV/IM at 0, 24, 48 hrs]:::action C --> F[OR Artemether 1.6 mg/kg IM at 0, 24, 48 hrs]:::action E --> G[Switch to oral ACT after 3 doses]:::action F --> G D --> H[Artemether-lumefantrine or artesunate-amodiaquine]:::action ``` **High-Yield:** Artesunate is the WHO-preferred agent for severe malaria (faster parasite clearance, lower mortality than quinine). Artemether is an acceptable alternative where artesunate is unavailable. Both are given for 3 parenteral doses, then switched to oral ACT. ## Why Not Chloroquine? *P. falciparum* is chloroquine-resistant in India (resistance established since 1970s). Chloroquine is contraindicated. ## Why Not Quinine? Quinine is now **second-line** for severe malaria. Artesunate/artemether are superior in efficacy and safety (lower hypoglycemia, ototoxicity risk). Quinine is reserved only when parenteral artesunate/artemether unavailable. ## Why Not Atovaquone-Proguanil? Atovaquone-proguanil is an oral agent suitable only for **uncomplicated** malaria. It is contraindicated in severe malaria with organ dysfunction. **Clinical Pearl:** Severe malaria is a medical emergency. Parenteral therapy must be initiated immediately; delay increases mortality. After 3 parenteral doses and clinical improvement, switch to a complete course of oral ACT (usually artemether-lumefantrine or artesunate-amodiaquine for 3 days total).